{"entity":{"id":"jonathan-strosberg","kind":"person","name":"Jonathan R. Strosberg","aka":[],"tldr":"Led NETTER-1, the trial that made lutetium dotatate the first approved radioligand therapy for neuroendocrine tumours.","summary":"Jonathan Strosberg was principal investigator of NETTER-1, which showed 177Lu-DOTATATE reduces the risk of progression by 79% in midgut neuroendocrine tumours and led to Lutathera's approval, the first radioligand therapy approved for a solid tumour and the template for PSMA-targeted therapy. He co-leads the NETTER-2 and COMPETE programmes and chairs the North American Neuroendocrine Tumor Society guidelines.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Strosberg%20J%5BAuthor%5D%20neuroendocrine%20lutetium"}],"tags":["neuroendocrine","radioligand","trialist"],"related":[],"cancers":["neuroendocrine"],"sections":[],"technologies":["radioligand-therapy"],"targets":["sstr2"],"drugs":["lutathera"],"companies":[],"institutions":["moffitt"],"pathways":[],"terms":[],"trials":["compete"],"people":[],"bottlenecks":[],"keyPapers":["paper-netter-2-lancet-2024"],"journals":[],"dependsOn":[],"notes":[],"role":"Section Head, Neuroendocrine Tumor Program, Moffitt Cancer Center","institutionId":"moffitt","specialisms":["Neuroendocrine tumours","Peptide receptor radionuclide therapy","Somatostatin analogues","Radioligand trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Strosberg%20J%5BAuthor%5D%20neuroendocrine%20lutetium"}],"papers":[{"title":"Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors (NETTER-1)","journal":"NEJM","year":2017,"doi":"10.1056/NEJMoa1607427"},{"title":"177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results","journal":"Lancet Oncology","year":2021,"doi":"10.1016/S1470-2045(21)00572-6"},{"title":"NETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours","journal":"The Lancet","year":2024,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NETTER-2+lutetium+dotatate+first-line+Singh+Lancet"}]},"route":"/people/jonathan-strosberg/","neighbours":{"cancer":[{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"}],"technology":[{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/"}],"target":[{"id":"sstr2","kind":"target","name":"Somatostatin receptor 2","route":"/targets/sstr2/"}],"drug":[{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/"}],"institution":[{"id":"moffitt","kind":"institution","name":"Moffitt Cancer Center","route":"/institutions/moffitt/"}],"trial":[{"id":"compete","kind":"trial","name":"COMPETE","route":"/trials/compete/"}],"paper":[{"id":"paper-netter-2-lancet-2024","kind":"paper","name":"NETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours","route":"/key-papers/paper-netter-2-lancet-2024/"}]}}